Proactive Research has published a new note on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) ahead of the launch of iron deficiency drug Accrufer in the US.
In Europe, the drug is branded as Ferracru and marketed by partner Norgine.
Accrufer is an effective oral product to treat iron deficiency (anaemia), says Proactive analyst John Savin.
In addition, Accrufer is positioned against ineffective, if cheap, generic oral iron products that have significant gastrointestinal side effects.
“This makes Shield one of the few UK companies to both achieve full FDA approval and to gain the maximum US-market profit from its R&D investments. “
Savin’s note looks at the current position of Accrufer ahead of potential trading updates and FY21 results over the next few months.
